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Chronic Diseases Requiring Hospitalization and Risk
of Non-Melanoma Skin Cancers—A Population Based
Study from Denmark
Annette Ø. Jensen1,2,3, Anne B. Olesen1,4, Claus Dethlefsen5, Henrik T. Sørensen2 and Margaret R. Karagas3
We examined the associations between chronic diseases requiring hospitalization and the risk of non-
melanoma skin cancers (NMSCs) in a population-based case–control study of 4,187 patients diagnosed with a
first primary NMSC in 1995 in Denmark. From the National Patient Registry covering all Danish hospitals, we
obtained data on hospitalizations with chronic diseases, recorded before the date of NMSC diagnosis. Using
incidence density sampling, we selected 10 age-, gender-, and residence-matched controls from the Danish Civil
Registration System. We used conditional logistic regression to compute incidence rate ratios (IRRs) and 95%
confidence intervals (CIs). Although no overall association was found between basal cell carcinoma (BCC) and
hospitalization for chronic diseases, an elevated IRR for BCC was found among patients with connective tissue
disease (IRR 1.34 (95% CI: 0.99–1.82)), transplants (IRR 8.00 (95% CI: 2.15–30)), and lymphoma (IRR 2.50 (95% CI:
1.29–4.84)). An overall association between squamous cell carcinoma (SCC) and hospitalization for chronic
diseases was found and specific among patients with leukemia (IRR 7.75 (95% CI: 2.35–26)), lymphoma (IRR 3.86
(95% CI: 0.99–15)), and skin diseases (IRR 5.28 (95% CI: 1.95–14)). Our study supports the presence of an association
between certain chronic diseases and NMSC, and further suggests that these results unlikely are due to bias.
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INTRODUCTION
An increased risk of non-melanoma skin cancer (NMSC) has
been observed for patients with several chronic diseases,
including other solid cancers (Frisch and Melbye, 1995; Frisch
et al., 1996; Karagas et al., 1998, 1999; Milan et al., 2000;
Rosenberg et al., 2004), psoriasis (Frentz and Olsen, 1999),
atopic dermatitis (Olesen et al., 2005), rheumatologic diseases
(Mellemkjaer et al., 1996), and lymphoma (Hjalgrim et al.,
2000). Further, elevated NMSC risks have been reported
following certain treatments like radiation therapy and photo-
therapy, psoralen and long-wave ultraviolet radiation (psoralen
plus ultraviolet light A (PUVA)) (Saladi and Persaud, 2005), and
use of immunosuppressants (Karagas et al., 2001; Sorensen et al.,
2004) including among transplant recipients (Hartevelt et al.,
1990; Caforio et al., 2000; Wong et al., 2003). These studies
generally focused on single risk factors or single treatments, and
still it is not clear if the increased risk of NMSC is due to the
chronic diseases or the treatments required for these diseases.
In a previous nationwide cohort study of NMSC patients in
Denmark, we found a lower mortality among basal cell
carcinoma (BCC) patients compared with that of the general
Danish population (Jensen et al., 2006). This led us to
speculate that the observed links between chronic disease
and NMSC might be due to biases such as surveillance bias
(Berkson, 1946; Sorensen et al., 1996).
Therefore, we evaluated any association between NMSC
and chronic diseases overall, using the population-based
Danish National Patient Registry. Further, we examined
whether a previous history of hospitalization for selected
chronic diseases was a risk factor for a subsequent diagnosis
of NMSC. To examine potential bias, our study design
included additional analyses to rule out the effect of
surveillance and selection bias on our results.
RESULTS
Descriptive data
We restricted our analyses to first primary cases, including
cases with BCC (N¼ 3,801, 91%) and squamous cell
carcinoma (SCC) (N¼386, 9%). Patients with BCC were,
on average, younger than patients with SCC, with men
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accounting for about a half of the BCC patients and for about
two-thirds of SCC patients (data not shown).
Chronic diseases as risk factors for BCC
Previous hospitalization for a connective tissue disease
occurred in 1.3% of BCC cases and 1% of the controls.
Organ transplantation occurred in 0.1% of the BCC cases
compared with 0.01% of controls. A total of 0.3% cases and
0.1% controls had a previous hospitalization for lymphoma.
Cases with BCC and their controls did not differ with respect
to prevalence of cardiovascular disease, chronic pulmonary
disease, renal disease, solid cancer, leukemia, or any severe
skin disease (Table 1).
Chronic diseases as risk factors for SCC
Four percent of the SCC cases and 3% of their controls had a
prior hospitalization for chronic pulmonary disease. Organ
transplantation occurred in 0.3% of the SCC cases compared
with 0.03% of the controls. Leukemia hospitalizations had
occurred in 1% SCC cases and 0.2% controls. A total of 0.8%
of the SCC cases and 0.2% controls were previously
hospitalized for lymphoma. Hospitalization for a severe skin
disease occurred in 2% of SCC cases and 0.3% of controls.
The prevalence of the other chronic diseases, we examined,
were similar among SCC cases and controls (Table 1).
Chronic diseases and the overall risk of NMSC
Eighty-seven percent of all cases with BCC had no chronic
diseases before the date of diagnosis in 1995; the remaining
13% had at least one chronic condition that required
hospitalization. A similar proportion was observed among
the controls, with an incidence rate ratio (IRR) for BCC of 1.03
(95% confidence interval (CI): 0.93–1.14) among patients with
at least one chronic disease. The IRR was 1.01 (95% CI:
0.90–1.13) for the medium (Charlson Comorbidity Index
(CCI)¼ 1–2) compared with the low comorbidity level
(CCI¼ 0). The IRR was 1.14 (95% CI: 0.92–1.42) for high
(CCI42) compared with the low comorbidity level (CCI¼0)
(data not shown). After excluding disease categories, which are
known to increase the risk for NMSC, the IRR for BCC was
0.97 (95% CI: 0.90–1.05) (Table 1, bottom).
Among cases with SCC, 77% had no hospitalizations for
chronic diseases before the date of diagnosis in 1995, and
23% had at least one chronic disease requiring hospitaliza-
tion. Among the controls, the respective prevalence before
the index date was 83% and 17%. The overall IRR for SCC
was 1.47 (95% CI: 1.14–1.91) in those with at least one
chronic disease. Compared with patients with low comor-
bidity level (CCI¼ 0), the IRR was 1.27 (95% CI: 0.95–1.71)
in SCC patients with medium comorbidity level (CCI¼ 1–2)
and 2.46 (95% CI: 1.55–3.90) with high comorbidity level
(CCI42) (data not shown). After excluding disease cate-
gories, which are known to increase the risk for NMSC, the
IRR for SCC was 1.11 (95% CI: 0.86–1.43) (Table 1, bottom).
High-risk versus low-risk BCC and SCC
We found a similar proportion of cases and controls having
had a history of hospitalization for a chronic disease when
defining risk profile for BCC according to tumor size (X20 mm
vso20 mm). The IRR (X20 mm) was 1.59 (95% CI: 1.10–2.29)
Table 1. Distribution of chronic diseases in cases with first primary NMSC in a Danish case serie in 1995 and
controls
Basal cell carcinomas Squamous cell carcinomas
Number of
cases
(N=3,801)
Number of
controls
(N=37,643)
IRR
(95% CI)
Number of
cases (N=386)
Number of
controls
(N=3,671) IRR (95% CI)
Hospital diagnoses before index date
CVD 239 (6%) 2,267 (6%) 1.05 (0.91–1.20) 44 (11%) 338 (9%) 1.23 (0.87–1.73)
Chronic pulmonary disease 76 (2%) 759 (2%) 1.00 (0.78–1.26) 17 (4%) 94 (3%) 1.70 (0.99–2.91)
Connective tissue disease 49 (1.3%) 362 (1.0%) 1.34 (0.99–1.82) 6 (2%) 35 (1%) 1.41 (0.55–3.61)
Moderate to severe renal disease 14 (0.4%) 104 (0.3%) 1.34 (0.76–2.33) 2 (0.5%) 8 (0.2%) 2.50 (0.53–12)
Organ transplants 4 (0.1%) 5 (0.01%) 8.00 (2.15–30) 1 (0.3%) 1 (0.03%) 10.00 (0.63–160)
Any solid cancer except skin cancer 129 (3%) 1,149 (3%) 1.12 (0.93–1.35) 20 (5%) 124 (3%) 1.53 (0.94–2.49)
Leukemia 4 (0.1%) 32 (0.1%) 1.25 (0.44–3.53) 5 (1%) 7 (0.2%) 7.75 (2.35–26)
Lymphoma 11 (0.3%) 44 (0.1%) 2.50 (1.29–4.84) 3 (0.8%) 7 (0.2%) 3.86 (0.99–15)
Any severe skin disease 18 (0.5%) 141 (0.4%) 1.20 (0.73–1.99) 6 (2%) 11 (0.3%) 5.28 (1.95–14)
The overall association between chronic diseases and NMSC:
Any chronic disease 506 (13%) 4,861 (13%) 1.03 (0.93–1.14) 89 (23%) 610 (17%) 1.47 (1.14–1.91)
Any chronic disease excluding disease categories
which are known to elevate the risk of NMSC1
452 (12%) 4,095 (11%) 0.97 (0.90–1.05) 82 (21%) 534 (15%) 1.11 (0.86–1.43)
CI, confidence interval; CVD, cardiovascular disease; IRR, incidence rate ratio; NMSC, non-melanoma skin cancer.
1Excluding connective tissue disease, moderate to severe renal disease, organ transplants, solid cancers, leukemia and lymphoma, and severe skin disease.
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and the IRR(o20 mm) was 1.39 (95% CI: 0.97–1.98) for SCC
according to risk profile determined by tumor size. When
defining aggressive BCC by its histological profile, the IRR of
sclerosing BCC was modestly lower (IRR of 0.88 (95% CI:
0.68–1.14) than nodular, superficial, and ulcerative BCC (IRR
of 1.06 (95% CI: 0.95–1.18)). When defining aggressive SCC
according to level of differentiation, the IRR for a high-risk
tumor was 1.64 (95% CI: 1.18–2.28) and the IRR for a low-risk
tumor was 1.37 (95% CI: 0.86–2.18) (Table 2).
The impact of chronic diseases on the overall risk of NMSC in
different age groups
Chronic diseases were recorded in similar proportions among
BCC cases and controls in all age groups, with an IRR for BCC
of 1.03 (95% CI: 0.81–1.32) in those below 61 years of age,
an IRR for BCC of 1.01 (95% CI: 0.89–1.15) in those between
61 and 80 years of age, and an IRR for BCC of 1.09 (95% CI:
0.89–1.33) in those above 81 years of age (data not shown).
Chronic diseases were recorded in similar proportions among
SCC cases and controls below 61 years of age, with an IRR for
SCC of 0.82 (95% CI: 0.18–3.66). SCC cases older than 61 years
had a higher prevalence of at least one chronic disease requiring
hospitalization compared with the controls, with an IRR for SCC
of 1.88 (95% CI: 1.33–2.66) in those between 61 and 80 years of
age and an IRR for SCC of 1.18 (95% CI: 0.79–1.76) in those
above 80 years of age (data not shown).
DISCUSSION
Our study supports the presence of an association between
certain chronic diseases and non-melanoma skin cancer.
However, a major limitation of our study is that despite our
large study size, our risk estimates were imprecise when we
examined specific chronic diseases, in particular because of a
very small numbers of SCC cases. Nonetheless elevated risks
of NMSC were seen among patients with connective tissue
disease, organ transplants and lymphoma, and severe skin
diseases. These results are consistent with recent findings
(Hartevelt et al., 1990; Mellemkjaer et al., 1996; Frentz and
Olsen, 1999; Caforio et al., 2000; Hjalgrim et al., 2000;
Wong et al., 2003; Olesen et al., 2005) suggesting that
general immunosuppression is a major reason for NMSC
development. How a condition with a chronic disease in
general affects the immune system, and thereby the risk of
NMSC, is less well known. The fact that the association
persisted for SCC even after excluding disease categories,
affecting the immune system and which are known to
increase the risk for NMSC, indicates a relation between a
chronic disease condition, the immune system, and NMSC.
We additionally found that individuals with chronic
pulmonary disease were at higher risk of SCC, which to our
knowledge has not been reported previously. One explana-
tion is that smoking is associated both with SCC (Karagas
et al., 1992; De Hertog et al., 2001) and chronic pulmonary
disease. Another explanation is that steroid treatment is
associated both with SCC (Karagas et al., 2001; Sorensen
et al., 2004) and chronic pulmonary disease.
A major strength of our study is that we evaluated if our
results were subject to surveillance bias. Arguing against
surveillance bias, is that we found no overall association
between the level of comorbidity and BCC risk. Moreover, if
Table 2. Characteristics of cases with high- and low-risk NMSC according to size, histological features, and degree
of differentiation, and their corresponding controls
Low-risk tumor High-risk tumor
Number
of cases
Number
of controls
IRR
(95% CI)
Number
of cases
Number
of controls
IRR
(95% CI)
Hospital diagnoses
before index date
o20mm BCC X20mm BCC
No 2,096 (88%) 20,646 (87%) 1 (ref.) 1,199 (85%) 12,136 (87%) 1 (ref.)
Yes 299 (12%) 3,055 (13%) 0.96 (0.84–1.09) 207 (15%) 1,806 (13%) 1.15 (0.98–1.35)
Nodular, superficial, and ulcerative BCC Sclerosing BCC
No 2,723 (86%) 27,222 (87%) 1 (ref.) 572 (89%) 5,560 (87%) 1 (ref.)
Yes 432 (14%) 4,048 (13%) 1.06 (0.95–1.18) 74 (11%) 813 (13%) 0.88 (0.68–1.14)
o20mm SCC 420mm SCC
No 147 (77%) 1,506 (82%) 1 (ref.) 150 (77%) 1,555 (84%) 1.0 (ref.)
Yes 45 (23%) 320 (18%) 1.39 (0.97–1.98) 44 (23%) 290 (16%) 1.59 (1.10–2.29)
Well-differentiated SCC1 Moderate to poorly differentiated SCC1
No 95 (79%) 977 (84%) 1 (ref.) 170 (75%) 1,771 (83%) 1 (ref.)
Yes 25 (21%) 190 (16%) 1.37 (0.86–2.18) 57 (25%) 351 (17%) 1.64 (1.18–2.28)
BCC, basal cell carcinoma; CI, confidence interval; IRR, incidence rate ratio; NMSC, non-melanoma skin cancer; SCC, squamous cell carcinoma.
1We only had information on level of differentiation on 347 (89%) cases of SCC.
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surveillance bias were present, we would expect an
increased detection of smaller BCCs, which was not evident.
In fact, if anything, an inverse relation was found. We found a
stronger impact of a higher level of comorbidity on SCC risk
compared with a lower level, raising the possibility of
surveillance bias. However, we did not find that associations
differed according to tumor size and level of differentiation of
the SCCs, which would have supported the possibility of
surveillance bias.
The validity of case–control studies depends partly on the
comparability of cases and controls, dependent on the
manner in which they are selected (Karagas, 1993). A major
strength of our study compared with others is the availability
of inpatient and outpatient skin cancer cases, as well as cases
from different specialists (dermatologists, oncologists, plastic
surgeons, and general practitioners), resulting in representa-
tion of a wide spectrum of NMSC severity. Additionally, we
were able to select controls from the general population,
thereby obtaining an unbiased control group (Karagas, 1993).
We further considered the possibility of under-ascertainment
of especially BCC in patients with severe diseases (due to the
triviality of BCC compared with this other disease). This
would introduce a bias due to systematic differences in
characteristics between those who are selected for study and
those who are not (Jepsen et al., 2004), because the selection
of BCC cases would relate to patients with less severe chronic
diseases. Potentially, this would lead to underestimation of
the overall effect of chronic diseases on the risk of BCC
(Brenner and Hakulinen, 2005). We would expect this
phenomenon to preferentially affect older patients; however,
in our age-stratified analyses we found a similar risk of BCC
in both younger and older age groups, arguing against this
type of bias.
Another advantage of our study is that we used the
discharge diagnoses from the Danish National Patient
Registry, which comprises data on 99.4% of all discharges
from Danish non-psychiatric hospitals, thereby avoiding
recall bias (Karagas, 1993). However, this is also a limitation
because we have only assessed severe cases of chronic
diseases and not the more common conditions that may not
require hospitalization (ie, hypertension and diabetes).
Another major limitation is that we were unable to adjust
for the medications taken for the chronic diseases associated
with an increased risk of NMSC. Therefore, we cannot
completely rule out whether the association observed
represents a biological or treatment effect.
In conclusion, we found an association between chronic
diseases and BCC and SCC. This association persisted for SCC
even after excluding disease categories, which are known to
increase the risk of NMSC. Our results are unlikely due to
biases but we cannot completely rule out that the observed
associations represent a treatment effect.
MATERIALS AND METHODS
Cases of NMSC
In 1995, Professor Gerda Frentz established a nationwide case series
by prospectively documenting all patients with NMSC seen by
Danish dermatologists in 1995. Two sources were used to establish
the series. The first included patients seen at private or public
outpatient dermatology clinics, where the following clinical data
were available: tumor site, size, and clinical diagnosis, whether the
biopsy was sent for histological review, treatment type, and history
of NMSCs. The second source comprised all patients with a
histology review of suspected NMSCs, sent from any other non-
dermatology practitioner to a pathologist. These data also included
biopsies diagnosed as NMSC, irrespective of the clinical diagnosis.
Histological data on these tumors included the final histological
diagnosis, the type of referring clinic, and if appropriate, details on
the tumor’s growth pattern, differentiation, and excision borders.
We classified tumors into high-risk and low-risk groups (Miller,
2000) according to tumor size (low risk as below 20 mm and high
risk as above 20 mm), histological features of BCC tumors (nodular,
superficial, and ulcerative were considered low risk, whereas
sclerosing tumors were considered high risk), and the level of
differentiation for SCC tumors (well-differentiated tumors were
considered low risk, and poor or moderately differentiated ones
were considered high risk; data missing on 11%).
All cases of the case serie were ascertained with a histological
diagnosis performed by a dermatopathologist. Data on a history of
NMSC were unavailable on this second source of cases in the case
serie, and therefore were obtained by linkage to the Danish Cancer
Registry (the Danish Cancer Registry is a population-based registry
containing nationwide data on cancer cases since 1943; Storm et al.,
1997). Overall, there were 10,749 skin cancer patients (6,529 from
the first source and 4,220 from the second source). These excluded
1,040 patients with Bowens Disease, keratoacanthoma and actinic
keratosis, and other clinically misclassified as NMSCs. The remain-
ing (9,709 patients) comprised first primaries (N¼ 4,187) and new
subsequent cases, as well as cases with an unknown history of
NMSC (N¼ 5,522). We only included cases with first primaries in
the analyses.
General population controls
A unique 10-digit civil registration number, assigned to all Danish
residents by the Danish Civil Registration System (Frank, 2000),
allows unambiguous data linkage between national registries. The
Civil Registration System, which is updated daily, contains informa-
tion for all Danish residents on vital status, date of death, and the
area of residence. Approximately, 10 controls for each case were
individually matched on age, gender, and area of residence, based
on incidence density sampling (Wacholder et al., 1992); that is the
controls had to be alive and at risk for a first NMSC at the time the
corresponding case was diagnosed in 1995 (the index date assigned
to controls). Data on the 41,314 controls were extracted.
Hospitalization due to chronic diseases
From the Danish National Patient Registry, we retrieved all
hospital discharge diagnoses recorded between 1 January 1977
(the date the registry was established) and the date of the
NMSC diagnosis for cases or index date for controls. Diagnoses
were coded in ICD-8 system through 1993 and in the ICD-10
system thereafter. The National Patient Registry records 99.4%
of all discharge records from Danish hospitals (Andersen et al.,
1999).
We examined the association of chronic diseases on the overall
risk of NMSC by classifying diagnoses of chronic diseases into the
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following nine categories: cardiovascular disease, chronic pulmo-
nary disease, connective tissue disease, moderate to severe renal
disease, organ transplants, cancer, leukemia, lymphoma, and severe
skin disease (Table 3).
We further examined the association of the level of chronic
morbidity on the risk of NMSC by using the original diagnostic
categories from the CCI (a validated index, developed to predict 1-
year patient mortality using comorbidity data obtained from hospital
chart review). In addition to conditions included as part of the CCI,
we examined discharge diagnoses of patients with an organ
transplant and severe skin diseases. Three levels of the comorbidity
score were defined as follows: 0 (‘‘low’’) for persons with no
underlying diseases listed in the Charlson Index; 1–2 (‘‘medium’’);
and42 (‘‘high’’) according to the disease categories of the originally
CCI (Charlson et al., 1987).
To evaluate whether the relation between chronic diseases and
NMSC is only due to immune-related chronic diseases, we examined
the remaining association of chronic morbidity after excluding
disease categories, which are known to increase the risk of NMSC in
the analyses (the categories of connective tissue diseases, renal
diseases, organ transplants, cancer, leukemia, lymphoma, and
severe skin diseases).
Statistical analysis
We used conditional logistic regression to compute incidence rate
ratios IRRs and 95% CIs for NMSC, according to the chronic diseases
overall and for each category (when using incidence density
sampling, the estimated exposure odds ratio in a case–control design
is an unbiased estimate of the IRR; Szklo and Nieto, 2000).
To evaluate the presence of surveillance bias, we compared risk
of NMSC across comorbidity levels of the CCI. Further, we
compared the risk of high-risk (aggressive tumor behavior) versus
low-risk tumors (less aggressive tumor behavior) according to size,
histological feature, and level of differentiation (Miller, 2000).
To examine a potential selection bias among cases being
ascertained and cases not being ascertained, we conducted the
analyses stratified by age groups (o61, 61–80, andX81 years). This
analysis allowed us to explore if this phenomenon was differentially
present as an indication of selection bias.
We considered BCC and SCC separately, and assigned patients to
the category of SCC if both types were present. We analyzed data
using STATAs software (version 9.0, STATA, College Station, TX).
The study was approved by the Danish Data Protection Agency.
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Table 3. Translation of disease categories of chronic diseases into discharge diagnoses in ICD-8 and ICD-10
Disease category Diseases ICD-8 ICD-10
Cardiovascular disease (CVD) Acute myocardial infarction,
congestive heart disease, peripheral
vascular disease, and
cerebrovascular disease
410; 427.09; 427.10; 427.11;
427.19; 428.99; 782.49; 440–445;
430–438.
I21–I23; I50; I11.0; I13.0; I13.2;
I70–I74; I77; I60–I69; G45–G46
Chronic pulmonary disease Emphysema, asthma, and chronic
obstructive lung disease
490–493; 515–518 J40–J47; J60–J67; J68.4; J70.1; J70.3;
J84.1; J92.0; J96.1; J98.2; J98.3
Connective tissue disease Diffuse connective tissue disease,
rheumatoid arthritis and other
inflammatory polyarthropathies, and
polymyalgia rheumatica
712; 716; 734; 446; 135.99 M05; M06; M08; M09; M30–M36;
D86
Moderate to severe renal
disease
Glomerulonephritis, nephropathies,
and end-stage renal disease
403; 404; 580–583; 584; 590.09;
593.19; 753.10–753.19; 792
I12; I13; N00–N05; N07; N11; N14;
N17–N19; Q61
Organ transplants Heart, kidney, liver, and bone
marrow transplantation
Y9509 Z94
Any solid cancer except skin
cancer and metastasis
Any solid cancer except skin cancer
and metastasis
140–199, except173 C00–C80, except C44
Leukemia 204–207 C91–C95
Lymphoma Non-Hodgkin and Hodgkin
lymphoma, and multiple myeloma
200–203; 275.59 C81–C85; C88; C90; C96
Any severe skin disease Sunburns, urticaria, psoriasis, contact
dermatitis, atopic dermatitis, and
bullous dermatoses
690–698 L10–L59
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